Introduce your company
Optos was founded 25 years ago by Douglas Anderson. The motivation for the start of the company came when his son, Leif, developed a retinal detachment and became blind in one eye at the age of five. The ophthalmologist explained to Mr Anderson that he could not see the retinal detachment developing into the periphery of the eye with the technology available at the time. Mr Anderson, a medical engineer, thought ‘that’s not good enough’ and that there must be a way to design the technology so it can produce a single, high-resolution, ultra-widefield image of the retina – potentially enabling the diagnosis and prevention of retinal detachments and other conditions that are first seen in the periphery. After developing various prototypes, Optos launched the first generation of optomap® products that have evolved ever since.
Common applications for ultra-widefield include the early diagnosis and treatment of diabetic retinopathy, retinal tears and detachments, as well as the early detection of age-related macular degeneration, glaucoma, uveitis and non-eye diseases such as high blood pressure, heart disease and certain cancers.
Talk us through your latest innovations
We launched our latest innovation at 100% Optical 2017, the Daytona plus. 2017 has been a fantastic year for Optos and we’re thrilled that Daytona plus is a shortlisted nominee for ‘Product of the Year’ at the AOP Industry Awards 2018. The nomination is testament to how far ultra-widefield retinal imaging technology has come, since Douglas Anderson began the journey 25 years ago.
Daytona plus is a truly unique product which delivers superior retinal imaging and software options. Everything from its modern, sleek design, to its enhanced diagnostic power backed by 500+ peer reviewed optomap clinical studies and thousands of publications, continues to support its long term value. Crucially, Daytona plus captures a 200° high-resolution image of the retina, something no other device is capable of in a single scan - utilising the Auto Montage functionality increases the field of view to approximately 220o. By comparison, traditional retinal imaging techniques can only capture 45° - 100o of the retina in a single image.
Do you have any product launches lined up for 100% Optical 2018, what can visitors expect to see at your stand, and who do you hope to meet?
We said it last year, and we say it again. We love to image people and showing off our amazing - and unique - technology! We want visitors to stop by stand M250 and experience the optomap ‘WOW’ factor for themselves. The full team will be on hand throughout the three day event to image visitors and more than happy to help assess how the technology integrates into their optometry practice to raise clinical standards of care, differentiate from competitors and ultimately help run a growing, successful business.
New for 2018, we will be hosting on-stand CET, currently we are looking at 3 sessions per day! Several leading optometrists will be lecturing on ultra-widefield. It doesn’t matter if delegates are at the beginning of their journey and still wondering what all the fuss is about, or they may already own an OCT and trying to decide if the additional investment in ultra-widefield is the right route for them.
Most of all we want to tell independents that when buying ultra-widefield equipment for their practice, it is important to ensure that it will provide a unique function that helps them differentiate from competitors while also creating value for your practice, ideally in terms of creating an additional stream of revenue or a higher standard of clinical care. There really is no comparison to the optomap technology; we simply advise that delegates book a free trial to see how this unique technology could complement existing services within their practice.
What projects have you been involved in that you’re most proud of?
We are proud of Optos’ entire 25 year journey. Optos are now part of the Nikon group and enjoy access to their unsurpassed expertise and R&D in the field of optics, and are developing an exciting array of new products that will become available over the next few years. Earlier this year we announced a strategic alliance with Verily Life Sciences LLC, formerly known as Google Life Sciences, to develop machine learning-enabled solutions. The partnership will combine ultra-widefield technology with Verily's machine learning technology to create technology and solutions to assist physicians and others treating diabetes in screening for DR and diabetic macular edema. This will, in turn, allow diabetes-treating physicians to make more efficient referrals to eyecare providers. And eyecare specialists will also be provided with assisted reading programs for easier disease diagnosis.
Gareth Steer: Vice-President European Sales at Optos